Loading...
Market
What will be the overall health outcomes associated with the new oral immunotherapy program for peanut allergies in Australia by the end of 2024?
2
Resolution / Starting Odds
Significant improvement • 25%
Moderate improvement • 25%
No change • 25%
Worsening conditions • 25%
Reports from Australian health authorities or published studies
Story
Australia Introduces World-First Oral Immunotherapy for Babies with Peanut Allergy
Jul 31, 2024, 02:04 AM
Australia has initiated a groundbreaking peanut allergy treatment for babies, marking the first time oral immunotherapy will be offered as part of a new standardised model of care in hospitals across the country. This world-first initiative aims to address the growing prevalence of peanut allergies among infants by providing a structured and controlled treatment protocol. The new approach is expected to significantly improve the quality of life for affected families and reduce the risk of severe allergic reactions. This landmark health initiative sets a new precedent in allergy treatment.
View original story
Similar markets
No issues found • 25%
Minor issues found • 25%
Significant issues found • 25%
Undetermined • 25%
Cancer risk reduction • 25%
Liver damage reduction • 25%
Immune system improvement • 25%
Reproductive health improvement • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Abbott found liable • 25%
Abbott not found liable • 25%
Mistrial declared • 25%
Case dismissed • 25%
Increased confidence • 25%
Decreased confidence • 25%
No change • 25%
Mixed opinions • 25%
No significant outcome • 25%
Legal reform proposed • 25%
DEC policy change • 25%
Public apology issued • 25%
No changes recommended • 25%
Some vaccines recommended for elimination • 25%
Enhanced safety protocols recommended • 25%
Comprehensive overhaul of vaccine policies • 25%
Mostly positive • 25%
Mixed • 25%
Mostly negative • 25%
Unchanged • 25%
Complete Response • 25%
Partial Response • 25%
Stable Disease • 25%
Progressive Disease • 25%
Less than 20% reduction • 25%
20% to 30% reduction • 25%
31% to 40% reduction • 25%
More than 40% reduction • 25%
Reduction by <25% • 25%
Reduction by 25-50% • 25%
Reduction by 50-75% • 25%
Reduction by >75% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%